NewsBenzingaLeerink Partners mantiene la recomendación de “Market Perform” sobre Myriad Genetics y eleva el precio objetivo a $8 Leerink Partners mantiene la recomendación de “Market Perform” sobre Myriad Genetics y eleva el precio objetivo a $8 Benzinga 2026.11.05 19:56 (GMT+0) Open on Benzinga Other news How Tokenized Nvidia Traded Through Two Weeks of Huang Headlines What Are Wall Street Analysts' Target Price for Lumentum Holdings Stock? Texas Pacific Land Stock: Analyst Estimates & Ratings Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66